KRAS mutations lead to abnormal cell proliferation and oncogenic transformation, promote cancer metastasis, and increase the resistance of several cancer types, including CRC, to chemotherapy and epidermal growth factor receptor (EGFR)-targeted therapy (30). Here, KRAS is linked to colorectal carcinoma.